Short answer
Biogen (BIIB) filed its Q1 2026 10-Q quarterly report on Apr 29, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2.5B (up 1.9% year over year) with net income of $320M.
Q1 2026 key financials · XBRL
- Revenue
- $2.5B
- +1.9% YoY
- Net income
- $320M
- +32.8% YoY
- EPS (diluted)
- $2.15
- +31.1% YoY
Source: XBRL data from the Biogen (BIIB) Q1 2026 10-Q on SEC EDGAR. USD.
Biogen Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Near-term headwinds: competition, pricing pressure, reimbursement uncertainty, tariffs, supply-chain disruptions, and currency fluctuations
Risk Factors
- Newly added acquisition risk: announced Apellis agreement, with benefits dependent on timely completion, integration, and commercialization of EMPAVELI and SYFOVRE
- Most materially updated healthcare reform risk: July 2025 OBBBA changes Medicaid eligibility and funding, with key provisions effective in 2027 and 2028
- Regulatory risk: potential MFN drug-pricing policy could tie U.S. prices to developed-country prices
- Near-term commercial risk: LEQEMBI remains in early U.S. and international launch stages, requiring adequate reimbursement and effective marketing
- Financial risk: revenue remains substantially dependent on continued product sales and financial rights in anti-CD20 programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biogen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.